Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9552W HIGH $3.23
Volume
857.72 K
Value Traded
5.41 M
Short % Float
9.42%
Days to Cover
5.3
+9.95%Week
-14.08%1 Month
-15.84%3 Month
+56.11%6 Month
-97.13%5 Year
-65.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
246.23 M
EPS (TTM)
-1.05
P/E Ratio
-
Ent. Value
91.86 M
Total Shares
119.82 M
Float Shares
114.23 M
Insiders
4.67%
Institutions
58.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FATE Catalyst Timeline
Dated clinical, regulatory and corporate events for Fate Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fate Therapeutics, Inc.
922Total events
18Upcoming
110Tier-1 (high impact)
2013 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Jamie Harrell appointed SVP, Market Development & Commercial Operations
▲Grant / FundingFT819Corporate
CIRM awarded $15.0 million CLIN2 grant to support RECLAIM-LN Phase 2 trial of FT819
refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN)source ↗
▲Trial InitiationFT819Trial
Commencement of RECLAIM-LN Phase 2 trial in lupus nephritis
lupus nephritissource ↗
▲First Patient DosedFT819Trial
First patient dosed in RECLAIM-LN Phase 2 trial
lupus nephritissource ↗
◆Oral PresentationFT819Presentation
Emerging data with FT819 in systemic sclerosis presented
systemic sclerosissource ↗
▲Full ResultsFT819Clinical Data
Data from first four SSc patients as of June 12, 2026 cutoff
Systemic Sclerosissource ↗
▲Trial InitiationFT839Trial
FT839 Phase 1/2 trial initiated following IND clearance
autoimmune diseasesource ↗
▲Oral PresentationFT819Presentation
Preliminary clinical data in SSc presented at ISSCR 2026
systemic sclerosissource ↗
▲Topline ReadoutFT819Clinical Data
Preliminary clinical data from SSc cohort as of June 12, 2026 cutoff
Systemic Sclerosissource ↗
◆Poster PresentationFT819Presentation
Safety and Efficacy of FT819 in SLE at EULAR 2026
systemic lupus erythematosus (SLE)source ↗
◆Oral PresentationFT839Presentation
Off-the-Shelf Dual-CAR T-Cell Therapy FT839 at EULAR 2026
autoimmune disease (rheumatoid arthritis, Sjogren's)source ↗
◆Oral PresentationFT819Presentation
Safety and Efficacy of FT819 with Reduced Conditioning in SLE: Phase 1 Study Supporting Same-Day Discharge
systemic lupus erythematosussource ↗
●Enrollment UpdateFT819Trial
Total patients dosed with FT819 across autoimmune indications
Autoimmune Diseasessource ↗
▲Oral PresentationFT819Presentation
Preliminary clinical data in SLE presented at EULAR 2026
systemic lupus erythematosussource ↗
◆Poster PresentationFT839Presentation
Preclinical data presentation at EULAR Annual Congress 2026
autoimmune diseasessource ↗
▲Oral PresentationFT836Presentation
Preliminary Phase 1 data for FT836 presented at ASCO 2026
colorectal cancersource ↗
◆Poster PresentationFT836Presentation
Preliminary Phase 1 Results of FT836 at ASCO 2026
solid tumorssource ↗
◆Oral PresentationFT836Presentation
Preliminary Phase 1 results of FT836 presented at ASCO 2026
metastatic colorectal cancersource ↗
◆Oral PresentationFT839Presentation
FT839: A Multi-Antigen Targeting Off-the-Shelf dual-CAR T cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases
autoimmune diseasessource ↗
●Enrollment UpdateFT819Trial
16 SLE patients treated in Regimen A; 13 completed at least one month of follow-up as of May 14, 2026 data cutoff
systemic lupus erythematosussource ↗
▲Topline ReadoutFT819Clinical Data
Phase 1 SLE data cutoff for FT819 Regimen A
systemic lupus erythematosussource ↗
◆Poster PresentationFT836Presentation
CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer
cancersource ↗
▲FDA Feedback ReceivedFT819FDA Meeting
FT819 selected into FDA CDRP Program
systemic lupus erythematosussource ↗
▲IND ClearanceFT836IND
FDA clearance of IND for investigator-initiated trial of FT836 in combination with daratumumab for multiple myeloma
multiple myelomasource ↗
◆Poster PresentationFT819Presentation
FT819 Drives B cell Compartment Remodeling of Patients with Systemic Lupus Erythematosus Without Conditioning Chemotherapy
systemic lupus erythematosussource ↗
◆Enrollment UpdateFT819Trial
Patient treatment at dose level 2 (900 million cells) initiated
systemic lupus erythematosussource ↗
▲Type B MeetingFT819FDA Meeting
FT819 selected for FDA CDRP program enabling additional CMC-focused Type B meetings
moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritissource ↗
◆Poster PresentationFT819Presentation
Poster presentation of FT819 clinical data in SLE at CCR-East 2026
systemic lupus erythematosus (SLE)source ↗
▲Oral PresentationFT819Presentation
Clinical data presentation at ASGCT Annual Meeting 2026 (Regimen B data)
systemic lupus erythematosussource ↗
◆Poster PresentationFT839Presentation
Preclinical data presentation at ASGCT Annual Meeting 2026
autoimmune diseasessource ↗
◆Oral PresentationFT836Presentation
FT836 updates at ASGCT Annual Meeting May 2026
advanced solid tumorssource ↗
◆Poster PresentationFT839Presentation
Poster presentation of preclinical data for FT839 at AACR Annual Meeting
hematological malignancies and autoimmune diseasessource ↗
◆Topline ReadoutFT836Clinical Data
Data cutoff April 20, 2026: nine patients enrolled, five efficacy-evaluable
metastatic colorectal cancersource ↗
▲Topline ReadoutFT819Clinical Data
Data cutoff April 9, 2026: FT819 without conditioning chemotherapy shows clinical responses in SLE patients
systemic lupus erythematosussource ↗
●IND SubmissionFT839IND
IND submission for FT839 Phase 1 basket autoimmune study
autoimmune diseases (SLE, SSc, AAV, IIM, RA)source ↗
●Poster PresentationFT839Presentation
Preclinical data presentation at AACR Annual Meeting 2026
autoimmune diseases and hematologic malignanciessource ↗
Past FDA Catalysts and PDUFA Decisions
How FATE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-18 | FT839 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 21%
Micro Cap(rank 139 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FT836 Small moleculeNCT07216105 | Non-Small Cell Lung Cancer | Phase 1 | RECRUITING | 119 | Jan 1, 2030 | ||||||
| FT819 Monoclonal antibodyNCT07570862 | Lupus Nephritis | Phase 2 | RECRUITING | 53 | Jan 31, 2030 | ||||||
| FT819 Small moleculeNCT06308978 | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) | Phase 1 | RECRUITING | 244 | Sep 30, 2042 | ||||||
| FT819 Small moleculeNCT04629729 | Lymphoma, B-Cell | Phase 1 | ACTIVE NOT_RECRUITING | 54 | Sep 30, 2039 | ||||||
| FT825 Small moleculeNCT06241456 | Advanced Solid Tumor | Phase 1 | RECRUITING | 351 | May 1, 2044 | ||||||
| FT839 Monoclonal antibodyNCT07800871 | ANCA-Associated Vasculitis (AAV) | Phase 1 | RECRUITING | 446 | Oct 1, 2040 | ||||||
| FT576 Cell therapyCompletedNCT05182073 | Multiple Myeloma | Phase 1 | COMPLETED | 31 | Oct 18, 2024 | ||||||
| FT522 Small moleculeCompletedNCT05950334 | Relapsed/Refractory B-Cell Lymphoma | Phase 1 | COMPLETED | 20 | Jun 30, 2025 | ||||||
| ProTmune Monoclonal antibodyCompletedNCT02743351 | Hematologic Malignancies | Phase 1 | COMPLETED | 96 | Nov 5, 2021 | ||||||
| FT500 Small moleculeCompletedNCT03841110 | Advanced Solid Tumors | Phase 1 | COMPLETED | 37 | Nov 15, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every FATE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FT819 RMAT | lupus nephritis | Phase 1 | 2026-10-26 | renal response: 100%; mean reduction in proteinuria: approximately 50%Read More | Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TAHL CINDYOfficer (See Remarks) | Sell | -38,800 589,355 held | $2.46 | 08/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FATE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 2.3 % (130 %) | 34.76 M | 12.87 M |
FATE Institutional Ownership Trends
FATE Short Interest
Shares sold short, counted twice a month.
9.42%
Short % of Float
of tradable shares sold short
10.8M
Shares Sold Short
+14.6% vs prior count
5.3 High
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FATE ranks across every disease it competes in
Competitive Position is a premium feature
See how FATE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFATE News
FATE▼ -2.8%today
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Fate Therapeutics presented updated Phase 1 data for FT819 at ASN Kidney Week 2026. The study showed a 100% renal response in active lupus nephritis patients at Month 6, with no serious toxicities reported. FT819 demonstrated significant improvements in lupus disease activity and fatigue, supporting its advancement into a Phase 2 trial.
Read more →FATEFate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations. Harrell brings over 25 years of experience in commercial leadership, particularly in autoimmune therapies. He will oversee the commercialization strategy for Fate's CAR T-cell therapies, including FT819 in the RECLAIM-LN Phase 2 trial, aiming to improve patient access to these treatments.
Read more →FATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics has announced the granting of stock options and restricted stock units to newly-hired employees as part of its inducement equity plan. The grants, approved by the Compensation Committee, aim to attract talent and align employee interests with company performance. The stock options and RSUs will vest over four years, contingent on continued employment.
Read more →FATEFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two major investor conferences in the fourth quarter of 2026. The conferences include the Jefferies Global Healthcare Conference in London and the Piper Sandler Annual Healthcare Conference in New York. The company aims to highlight its advancements in induced pluripotent stem cell-derived immunotherapies.
Read more →FATEFate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Fate Therapeutics has received a $15 million CLIN2 grant from the California Institute for Regenerative Medicine to advance its RECLAIM-LN Phase 2 trial of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory lupus nephritis. This funding aims to support the clinical development of a therapy that could transform treatment options for patients suffering from this severe condition. The trial will evaluate the safety and efficacy of FT819, which targets pathological B cells, potentially improving the quality of life for patients.
Read more →FATEFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics has been selected to present four abstracts on its off-the-shelf CAR T-cell therapies at the ACR Convergence 2026. The presentations will cover clinical data for FT819, patient perspectives on CAR T-cell therapy in lupus, and updates on the FT839 trial. The company aims to improve access to CAR T-cell therapies for patients with autoimmune diseases.
Read more →FATEFate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Fate Therapeutics announced the presentation of clinical data for its off-the-shelf CAR T-cell product candidate FT819 at the CCR – West 2026 meeting. The data highlights favorable tolerability and early efficacy in patients with systemic lupus erythematosus. The presentation supports the ongoing Phase 2 RECLAIM-LN trial for lupus nephritis, showcasing promising results in disease management.
Read more →FATEFate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics will participate in the 2026 Annual Cantor Global Healthcare Conference, discussing its CAR T-cell product candidate FT819 and the RECLAIM-LN Phase 2 trial for lupus nephritis. The event will take place from September 9-12, 2026, in New York. Management will also hold one-on-one meetings with investors.
Read more →FATEFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated the RECLAIM-LN clinical trial for FT819, targeting patients with refractory lupus nephritis. The trial aims to enroll approximately 53 patients and evaluate the efficacy and safety of FT819. The first patient has been dosed, and the study is expected to complete enrollment within 15-18 months. The trial benefits from RMAT designation, facilitating an accelerated regulatory pathway.
Read more →FATE▼ -7.4%on this newsshared move
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics reported its Q2 2026 financial results, highlighting the dosing of the first patient in the RECLAIM-LN Phase 2 trial for lupus nephritis using FT819. The FDA has cleared the IND application for FT839, advancing it into a Phase 1/2 trial for autoimmune diseases. Preliminary data from clinical trials shows promising results in systemic sclerosis, while the company maintains a strong cash position to support ongoing operations.
Read more →FATE▲ +6.1%on this news
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
Fate Therapeutics has received FDA clearance for its Investigational New Drug application for FT839, a dual-CAR T cell product candidate targeting CD19 and CD38. This advancement allows the company to initiate a Phase 1/2 clinical trial to evaluate FT839's effectiveness in treating various autoimmune diseases. The therapy aims to eliminate pathogenic immune cells while avoiding the need for conditioning chemotherapy.
Read more →FATEFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics announced that preliminary clinical data for FT819, an off-the-shelf CAR T-cell product candidate, will be presented at the ISSCR 2026 Annual Meeting. The data highlights the treatment's safety and efficacy in patients with systemic sclerosis, demonstrating significant improvements without serious adverse effects. FT819 aims to address unmet needs in autoimmune diseases.
Read more →FATEFate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics, Inc. has announced its participation in several investor conferences during the third quarter of 2026. The conferences include the Leerink Partners Therapeutics Forum, Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The company aims to showcase its innovative pipeline of iPSC-derived cellular immunotherapies.
Read more →FATEFate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics has appointed Laura Hamill to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. Her background in commercial operations and strategic management is expected to support the company's transition to a commercial-stage entity. Hamill's previous roles include significant positions at Gilead Sciences and Amgen, where she led substantial revenue growth.
Read more →FATEFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics presented promising data for its CAR T-cell therapies, FT819 and FT839, at the European Congress of Rheumatology. FT819, currently in Phase 1 trials, has shown rapid and sustained clinical improvements in patients with systemic lupus erythematosus (SLE) while maintaining a favorable safety profile. Treatment led to significant B-cell depletion and possible reconstitution towards a healthier immune response. The preclinical data for FT839 indicates its potential efficacy in treating rheumatoid arthritis without the need for conditioning chemotherapy, positioning both therapies as transformative options for autoimmune diseases.
Read more →FATETRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential 2026 Fate Therapeutics. All ri
Fate Therapeutics is advancing its pipeline of CAR T-cell therapies aimed at treating autoimmune diseases and cancer. The company has initiated a registrational trial for its product FT819, which targets systemic lupus erythematosus. With a focus on off-the-shelf therapies, Fate aims to improve patient access and simplify treatment processes. However, potential risks include uncertainties in clinical outcomes and regulatory approvals, which could impact the timelines for commercial launches.
Read more →FATE▼ -13.6%on this news· ran to -26% by day 3shared move
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Fate Therapeutics announced the granting of restricted stock units (RSUs) to two new non-executive employees as part of their inducement plan. This grant, totaling 67,300 shares, was approved by the Compensation Committee and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting employee retention.
Read more →FATEFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Fate Therapeutics presented promising clinical data for FT836 at the ASCO Annual Meeting, highlighting its ability to reduce tumor size in metastatic colorectal cancer without conditioning chemotherapy. The early Phase 1 results indicate favorable safety and efficacy, with no adverse effects reported. Notably, FT836 demonstrates the capacity for trafficking to tumor sites and persistence in tumor tissues. The company expresses optimism regarding its potential to transform treatment approaches for solid tumors, particularly in patients with limited options.
Read more →FATE▲ +14.1%on this news· ran to +29% by day 3
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced that it will present data on its off-the-shelf CAR T-cell therapies at the upcoming ASCO and EULAR annual meetings. The presentations will include preliminary results from the FT836 and FT819 programs, focusing on overcoming solid tumor escape mechanisms and improving patient discharge protocols. These advancements highlight the company's commitment to enhancing treatment options for cancer and autoimmune diseases.
Read more →About Fate Therapeutics, Inc.
Headquarters12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
BIOPHARMAWATCH ELITE PLUS
Trade the next FATE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime